Stopping Menopausal Hormone Therapy May Temporarily Increase Fracture Risk
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 30, 2025 -- Stopping menopausal hormone therapy initially leads to several years of elevated fracture risk; however, this risk then decreases, first becoming similar to and eventually lower than the risk in women who have never used hormone therapy, according to a study published online July 23 in The Lancet Healthy Longevity.
Yana Vinogradova, Ph.D., from the University of Nottingham School of Medicine in the United Kingdom, and colleagues conducted a nested case-control study using U.K. primary and secondary care data from the Clinical Practice Research Datalink to estimate fracture risk among past users of menopausal hormone therapy. Women aged 40 years and older with a first record for any fracture were matched at the fracture index date with up to five female controls with no fracture history (648,747 and 2,357,125 women, respectively).
Overall, 21.6 percent of cases and 21.9 percent of controls used menopausal hormone therapy for a median of 3.6 and 3.9 years, respectively. The researchers found that overall fracture risk was reduced for current use versus never use (odds ratios [95 percent confidence intervals], 0.76 [0.74 to 0.78] and 0.75 [0.73 to 0.76] for estrogen-only and estrogen-progestogen, respectively), then became higher at one to 10 years after discontinuation (odds ratios [95 percent confidence intervals], 0.99 [0.98 to 1.01] and 1.06 [1.05 to 1.08], respectively), and was lower again for more than 10 years after cessation (odds ratios [95 percent confidence intervals], 0.93 [0.91 to 0.94] and 0.95 [0.94 to 0.96], respectively). There was variation in risk levels by menopausal hormone therapy type and treatment duration.
"Our comparative illustration of observed patterns of fracture risk for short and long use can help doctors and patients when discussing menopausal hormone therapy treatment options, and to consider how fracture risk may change after stopping menopausal hormone therapy use," Vinogradova said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
ENDO: Osteoporosis Treatment Benefits Elderly Patients With Fragility Fracture
THURSDAY, July 17, 2025 -- Patients with osteoporosis who suffer a fragility fracture at age 80 years or older have better five-year outcomes if they receive treatment for...
AI Can Accurately Estimate Bone Mineral Density and Classify Osteoporosis
WEDNESDAY, July 16, 2025 -- An artificial intelligence (AI)-assisted diagnostic system can accurately estimate bone mineral density (BMD) and classify osteoporosis category...
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
TUESDAY, July 15, 2025 -- In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.